Targeted News Service

New Johnson & Johnson ICOTYDE(r) (icotrokinra) long-term data demonstrate robust 2-year results in the treatment of adults and adolescents with plaque psoriasis
October 09, 2026

NEW BRUNSWICK, New Jersey, Oct. 9 [Category: BizHealth & Beauty] -- Johnson and Johnson posted the following news release:

* * *

New Johnson & Johnson ICOTYDE(r) (icotrokinra) long-term data demonstrate robust 2-year results in the treatment of adults and adolescents with plaque psoriasis

*

Spring House, Pa. (October 9, 2026) - Johnson & Johnson (NYSE: JNJ) today announced new two-year results from the Phase 3 ICONIC-LEADa study eva . . .

Targeted News Service Document Request Form

This document is available to you by e-mail if you complete the form below with relevant information. There may be a fee for this article or ongoing service of similar materials. We will be in touch shortly.

Click here for more information about our products

Existing Customer Login

Targeted News Service Document Request Form